There are no established treatments for recurrent meningioma when surgical and radiation
options are exhausted. The epidermal growth factor receptor (EGFR) is often over …

Purpose: Aggressive meningiomas that progress after surgery/radiotherapy represent an
unmet medical need. Strong and constant expression of SSTR2A receptors and activation of …

Meningiomas that progress after standard therapies are challenging with limited effective
chemotherapy options. This phase II trial evaluated the efficacy of everolimus plus …

Background No proven effective medical therapy for surgery and radiation-refractory
meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase …

We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients
with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent …

Despite a low evidence level, some systemic therapies may be considered for patients with
recurrent meningioma not amenable to further surgery or radiotherapy. In recurrent high …

Purpose To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca,
Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in …

Meningiomas are the second most common primary brain tumor and are primarily treated
with surgery (with or without embolization) and radiotherapy. Increasingly today …

A number of challenges are apparent with respect to the use of chemotherapy or targeted
therapy for intracranial meningioma. First, there is very limited published literature that …

Platelet-derived growth factor (PDGF) and its receptors (PDGFR) are frequently coexpressed
in meningiomas, potentially contributing to their pathogenesis. The North American Brain …